IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Lower Extremity Peripheral Arterial Disease and Exercise Ischemia (CLASH)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Lower extremity peripheral arterial disease (LEPAD) is a highly prevalent chronic disease. Cardiovascular mortality of LEPAD patients at five years ranges between 18 to 30%. LEPAD is primarily caused by atherosclerosis that induces an inadequate blood flow to meet the tissues demand due to the narrowing of the arteries. An aggravation of the arterial lesions in LEPAD patients induces a worsening of patients' symptoms and a severe limitation of their walking capacity, contributing to an impairment of their quality of life. Despite maintaining a sufficient walking activity is essential for these patients, LEPAD patients lower their physical activity, which worsen the disease and potentially contribute to increase the risk of cardiovascular events and deaths.
In a recent study in LEPAD patients, we showed, from a one hour GPS recording, a high variability of the patients' walking capacity (i.e., walking distances between two stops induced by lower limbs pain). Results suggested that in most patients previous stop duration before each walk was a predictor parameter of this walking variability. Whether there is an optimal or minimal recovery time influencing the walking capacity in LEPAD patients has never been studied.
This study is a prospective, cross-sectional study in exercise pathophysiology.
The main goal is to determine, following a walk that induces ischemia, the influence of the recovery duration on the subsequent walking performance in LEPAD patients.
Secondary goals are :
- To determine the nature of the relationship between the recovery duration and subsequent walking performance.
- To study the relationship between exercise ischemia, pain evolution and previous recovery duration.
- To determine whether the experimental procedure influence the determination of an optimal of minimal recovery duration.
- To study the influence of recovery duration on walking capacity from community-based measurement.
It is expected to determine for the first time an optimal recovery duration that would maximize the walking capacity of LEPAD patients.
In the medium term :
- To give indications to the LEPAD patients to manage their pain in the community without lower their physical activity.
- To limit the functional decline of LEPAD patients.
- To influence the quality of life and cardiovascular mortality. This would deserve furthers studies.
| Condition | Intervention |
|---|---|
| Peripheral Arterial Diseases Intermittent Claudication | Other: Subsequent walking performance |
| Study Type: | Interventional |
| Study Design: | Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Supportive Care |
| Official Title: | Lower Extremity Peripheral Arterial Disease and Exercise Ischemia: Walking Capacity Variability, Pain Evolution and Pathophysiological Responses. The CLASH Study. |
- Coefficient of determination between the recovery duration and subsequent walking performance, obtained from individual regression analyses. [ Time Frame: 32 days ]Coefficient of determination between the recovery duration and subsequent walking performance, obtained from individual regression analyses.
- Coefficient of determination determined from different curves fitting [ Time Frame: 32 days ]Coefficient of determination determined from different curves fitting
- Coefficient of correlation between the level of ischemia during recovery and exercise ischemia and pain occurrence during subsequent walking [ Time Frame: 32 days ]Coefficient of correlation between the level of ischemia during recovery and exercise ischemia and pain occurrence during subsequent walking
- Coefficient of correlation between the optimal recovery duration measured on the laboratory and measures from community-based measurements. [ Time Frame: 32 days ]Coefficient of correlation between the optimal recovery duration measured on the laboratory and measures from community-based measurements
| Estimated Enrollment: | 40 |
| Study Start Date: | September 2014 |
| Estimated Study Completion Date: | October 2018 |
| Estimated Primary Completion Date: | July 2018 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Subsequent walking performance
Subsequent walking performance
|
Other: Subsequent walking performance
Subsequent walking performance
|
Detailed Description:
Primary Outcome Measure :
Coefficient of determination between the recovery duration and subsequent walking performance, obtained from individual regression analyses.
Secondary outcome measures :
- Coefficient of determination determined from different curves fitting.
- Coefficient of correlation between the level of ischemia during recovery and exercise ischemia and pain occurrence during subsequent walking.
- Coefficient of correlation between the optimal recovery duration measured on the laboratory and measures from community-based measurements.
Eligibility criteria :
Inclusion criteria :
- Age > 18 years.
- Ankle-to-Brachial index ≤ 0.90 ;
- Patient with symptom of intermittent claudication
- Maximal walking distance on treadmill < 500 m (treadmill protocol 3.2 km/h, 10% grade) ;
- Informed consent obtained
Exclusion criteria :
- Patients that do not understand the protocol and the recommendations of the study;
- Patients living far away from the university hospital (more than 50 km)
- Diabetic patients;
- Medical therapy for chronic management of pain;
- Contraindication(s) for walking;
- Patient with critical ischemia;
- Exercise limitations others than vascular reasons.
- Cardiovascular events within the three months before inclusion ;
- Pregnant women;
- Adults subject to legal protection.
Eligibility| Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Age > 18 years.
- Ankle-to-Brachial index ≤ 0.90 ;
- Patient with symptom of intermittent claudication
- Maximal walking distance on treadmill < 500 m (treadmill protocol 3.2 km/h, 10% grade) ;
- Informed consent obtained
Exclusion Criteria:
- Patients that do not understand the protocol and the recommendations of the study;
- Patients living far away from the university hospital (more than 50 km)
- Diabetic patients;
- Medical therapy for chronic management of pain;
- Contraindication(s) for walking;
- Patient with critical ischemia;
- Exercise limitations others than vascular reasons.
- Cardiovascular events within the three months before inclusion ;
- Pregnant women;
- Adults subject to legal protection.
Contacts and LocationsPlease refer to this study by its ClinicalTrials.gov identifier: NCT02041169
| Contact: Guillaume MAHE, MD | +33 (0)2.99.28.43.09 | guillaume.mahe@chu-rennes.fr | |
| Contact: Alexis Le Faucheur | +33 (0)2.99.05.94.19 | alexis.lefaucheur@bretagne.ens-cachan.fr |
| France | |
| Rennes University Hospital | Recruiting |
| Rennes, Brittany, France, 35033 | |
| Contact: Guillaume MAHE, MD | |
| Principal Investigator: Guillaume MAHE, MD | |
| Sub-Investigator: Antoine LUCAS, MD | |
| Sub-Investigator: Alain CARDON, MD | |
| Principal Investigator: | Guillaume MAHE, MD | Rennes University Hospital |
More Information
| Responsible Party: | Rennes University Hospital |
| ClinicalTrials.gov Identifier: | NCT02041169 History of Changes |
| Other Study ID Numbers: |
35RC13-9907-CLASH 2013-A01381-44 ( Other Identifier: ANSM ) 13/34-914 ( Other Identifier: CPP Ouest V ) |
| Study First Received: | January 14, 2014 |
| Last Updated: | January 16, 2017 |
Additional relevant MeSH terms:
|
Intermittent Claudication Ischemia Peripheral Arterial Disease Peripheral Vascular Diseases Pathologic Processes Atherosclerosis |
Arteriosclerosis Arterial Occlusive Diseases Vascular Diseases Cardiovascular Diseases Signs and Symptoms |
ClinicalTrials.gov processed this record on August 22, 2017